{"id":"fluzoparib-apatinib","safety":{"commonSideEffects":[{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Nausea/vomiting"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Hand-foot skin reaction"}]},"_chembl":{"chemblId":"CHEMBL3186534","moleculeType":"Small molecule","molecularWeight":"397.48"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fluzoparib inhibits poly(ADP-ribose) polymerase (PARP), preventing DNA repair in homologous recombination-deficient tumors and inducing synthetic lethality. Apatinib selectively inhibits vascular endothelial growth factor receptor 2 (VEGFR2), blocking tumor angiogenesis. The combination leverages both DNA damage accumulation and vascular disruption to enhance anti-tumor activity.","oneSentence":"Fluzoparib is a PARP inhibitor that blocks DNA repair, while apatinib is a tyrosine kinase inhibitor targeting VEGFR2, together enhancing anti-tumor effects through synthetic lethality and anti-angiogenesis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:13:07.815Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Ovarian cancer (BRCA-mutated or homologous recombination-deficient)"},{"name":"Gastric cancer"},{"name":"Other solid tumors in phase 3 evaluation"}]},"trialDetails":[{"nctId":"NCT06145308","phase":"PHASE2","title":"Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing","status":"RECRUITING","sponsor":"Peking Union Medical College","startDate":"2023-08-15","conditions":"Salivary Gland Carcinoma, Precision Therapy","enrollment":39},{"nctId":"NCT05582499","phase":"PHASE2","title":"Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-11-01","conditions":"Breast Neoplasm, Breast Cancer, Breast Tumors","enrollment":716},{"nctId":"NCT06255392","phase":"PHASE3","title":"Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-06-12","conditions":"Fludzoparib" and Anti-angiogenic, HRD-positive/HER2-negative Advanced Breast Cancer","enrollment":200},{"nctId":"NCT06913777","phase":"PHASE3","title":"Neoadjuvant SNF Precision Therapy Phase III","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-04-08","conditions":"Neoadjuvant Therapy","enrollment":404},{"nctId":"NCT07000344","phase":"NA","title":"A Study of Apatinib Combined With Letrozole With or Without Fluzoparib in Estrogen Receptor-Positive, Platinum-Sensitive Recurrent Ovarian Cancer Previously Treated With First-Line PARP Inhibitor","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-07-01","conditions":"Ovarian Cancer","enrollment":70},{"nctId":"NCT04517357","phase":"PHASE2","title":"A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2020-10-16","conditions":"Relapsed Ovarian Cancer","enrollment":100},{"nctId":"NCT04869488","phase":"PHASE2","title":"A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2021-07-19","conditions":"Metastatic Castration Resistant Prostate Cancer","enrollment":93},{"nctId":"NCT05594095","phase":"PHASE2","title":"SNF Platform Study of HR+/ HER2-advanced Breast Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-12-30","conditions":"Breast Neoplasm, Breast Cancer, Hormone Receptor Positive Tumor","enrollment":620},{"nctId":"NCT06539091","phase":"PHASE3","title":"Fluzoparib in Combination With Apatinib Mesylate for Maintenance Therapy in Stage III-IV Ovarian Cancer","status":"NOT_YET_RECRUITING","sponsor":"Anhui Provincial Hospital","startDate":"2024-10-01","conditions":"Epithelial Ovarian Cancer, Efficacy, Safety","enrollment":51},{"nctId":"NCT06188455","phase":"PHASE3","title":"Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian Cancer","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2024-12-01","conditions":"Ovarian Cancer","enrollment":37},{"nctId":"NCT06161272","phase":"PHASE2","title":"Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi","status":"UNKNOWN","sponsor":"Guangxi Medical University","startDate":"2023-12-10","conditions":"Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma","enrollment":80},{"nctId":"NCT06081595","phase":"PHASE2","title":"Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment","status":"NOT_YET_RECRUITING","sponsor":"Jin Li","startDate":"2023-10-30","conditions":"Relapsed Ovarian Cancer","enrollment":54},{"nctId":"NCT05932264","phase":"PHASE2","title":"Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2023-07","conditions":"NSCLC, Non-small Cell Lung Cancer","enrollment":60},{"nctId":"NCT03945604","phase":"PHASE1","title":"A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2019-06-04","conditions":"Triple Negative Breast Cancer","enrollment":32},{"nctId":"NCT03805399","phase":"PHASE1, PHASE2","title":"FUSCC Refractory TNBC Umbrella (FUTURE)","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2018-10-18","conditions":"Triple-negative Breast Cancer","enrollment":140},{"nctId":"NCT05479487","phase":"PHASE2","title":"Fluzoparib and Apatinib Versus Fluzoparib in Relapsed Ovarian Carcinoma Maintenance Treatment","status":"NOT_YET_RECRUITING","sponsor":"Xiaohua Wu MD","startDate":"2022-08-01","conditions":"Relapsed Ovarian Cancer","enrollment":132},{"nctId":"NCT03075462","phase":"PHASE1","title":"A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2017-03-09","conditions":"Ovarian Cancer, Triple Negative Breast Cancer","enrollment":98},{"nctId":"NCT04229615","phase":"PHASE3","title":"A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2020-06-02","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma","enrollment":690},{"nctId":"NCT04659785","phase":"PHASE1, PHASE2","title":"A Study of Fluzoparib Combined With Apatinib as Second-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer（FA-ES-SCLC）","status":"UNKNOWN","sponsor":"Tianjin Medical University Second Hospital","startDate":"2020-07-01","conditions":"Small Cell Lung Cancer Extensive Stage","enrollment":53},{"nctId":"NCT04296370","phase":"PHASE3","title":"A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2020-07-13","conditions":"Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation","enrollment":474},{"nctId":"NCT03645200","phase":"PHASE1","title":"Treatment of Carrying TP53 Harmful Mutations","status":"UNKNOWN","sponsor":"Tianjin Medical University Second Hospital","startDate":"2019-07-01","conditions":"Advanced Cancer","enrollment":60},{"nctId":"NCT03026881","phase":"PHASE1","title":"A Study of Fluzoparib Given in Combination With Apatinib and Paclitaxel in Gastric Cancer Patients","status":"UNKNOWN","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2017-01","conditions":"Recurrent and Metastatic Gastric Cancer","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Fluzoparib; Apatinib","genericName":"Fluzoparib; Apatinib","companyName":"Jiangsu HengRui Medicine Co., Ltd.","companyId":"jiangsu-hengrui-medicine-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fluzoparib is a PARP inhibitor that blocks DNA repair, while apatinib is a tyrosine kinase inhibitor targeting VEGFR2, together enhancing anti-tumor effects through synthetic lethality and anti-angiogenesis. Used for Ovarian cancer (BRCA-mutated or homologous recombination-deficient), Gastric cancer, Other solid tumors in phase 3 evaluation.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}